Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1538-7836|13|6|967-977

ISSN： 1538-7933

Source： JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol.13, Iss.6, 2015-06, pp. : 967-977

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 77-84

John Wiley & Sons Inc

Access to resources Recommend Favorite

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 370-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful Management of Massive Intraperitoneal Bleeding in a Hemophilia A Patient with Inhibitor by Surgical Debridement of the Incomplete Hematoma and Administration of Recombinant Factor VIII and Activated Factor VII

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 35, Iss. 5, 2007-01 ,pp. : 405-407

Karger

Access to resources Recommend Favorite

Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation

By Gielen-Wijffels S.   Mook W.   Geest S.   Ramsay G.  

Intensive Care Medicine, Vol. 30, Iss. 6, 2004-06 ,pp. : 1232-1234

Springer Publishing Company

Access to resources Recommend Favorite

Half‐life extended factor VIII for the treatment of hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S176-S179

John Wiley & Sons Inc

Access to resources Recommend Favorite